Evidence map›Paper›PMID 29684709›Full record

ArticleInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2018

The role of natural selection in shaping genetic variation in a promising Chagas disease drug target: Trypanosoma cruzi trans-sialidase.

Joseph P Gallant, Raquel Asunción Lima-Cordón, Silvia A Justi, Maria Carlota Monroy, Toni Viola, Lori Stevens

Abstract read
In one paragraph

Article in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Anti-Pharmaceutics · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Joseph P GallantDepartment of Biology, University of Vermont, Burlington, VT, United States; Department of Pharmacology, University of Vermont, Burlington, VT. United States.
Raquel Asunción Lima-CordónDepartment of Biology, University of Vermont, Burlington, VT, United States.
Silvia A JustiDepartment of Biology, University of Vermont, Burlington, VT, United States.
Maria Carlota MonroyBiology School, Universidad de San Carlos de Guatemala, Guatemala City, Guatemala.
Toni ViolaDepartment of Biology, University of Vermont, Burlington, VT, United States.
Lori StevensDepartment of Pharmacology, University of Vermont, Burlington, VT. United States. Electronic address: lori.stevens@uvm.edu.
University of Vermont · USUniversidad de San Carlos de Guatemala · GT

Funding

Chagas disease transmission: Genomic studies of the kissing bug Triatoma infestans to enhance control strategies for a neglected tropical diseaseR03AI126268 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI CAHAN, SARA, STEVENS, LORI · 2016 to 2017
$155k
NIAID NIH HHS R03 AI126268
6 · The paper itself

Abstract

Rational drug design creates innovative therapeutics based on knowledge of the biological target to provide more effective and responsible therapeutics. Chagas disease, endemic throughout Latin America, is caused by Trypanosoma cruzi, a protozoan parasite. Current therapeutics are problematic with widespread calls for new approaches. Researchers are using rational drug design for Chagas disease and one target receiving considerable attention is the T. cruzi trans-sialidase protein (TcTS). In T. cruzi, trans-sialidase catalyzes the transfer of sialic acid from a mammalian host to coat the parasite surface membrane and avoid immuno-detection. However, the role of TcTS in pathology variance among and within genetic variants of the parasite is not well understood despite numerous studies. Previous studies reported the crystalline structure of TcTS and the TS protein structure in other trypanosomes where the enzyme is often inactive. However, no study has examined the role of natural selection in genetic variation in TcTS. To understand the role of natural selection in TcTS DNA sequence and protein variation, we examined a 471 bp portion of the TcTS gene from 48 T. cruzi samples isolated from insect vectors. Because there may be multiple parasite genotypes infecting one insect and there are multiple copies of TcTS per parasite genome, all 48 sequences had multiple polymorphic bases. To resolve these polymorphisms, we examined cloned sequences from two insect vectors. The data are analyzed to understand the role of natural selection in shaping genetic variation in TcTS and interpreted in light of the possible role of TcTS as a drug target. The analysis highlights negative or purifying selection on three amino acids previously shown to be important in TcTS transfer activity. One amino acid in particular, Tyr342, is a strong candidate for a drug target because it is under negative selection and amino acid substitutions inactivate TcTS transfer activity. AUTHOR SUMMARY: Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and transmitted to humans and other mammals primarily by Triatomine insects. Being endemic in many South and Central American countries and affecting millions of people the need for new more effective and safe therapies is evident. Here, we examine genetic variation and natural selection on DNA (471 bp) and amino acid (157 aa) sequence data of the T. cruzi trans-sialdiase (TcTS) protein, often suggested as a candidate for rational drug design. In our surveyed region of the protein there were five amino acid residues that have been shown to be integral to the function of TcTS. We found that three were under strong negative selection making them ideal candidates for drug design; however, one was under balancing selection and should be avoided as a drug target. Our study provides new information into identifying potential targets for a new Chagas drug.

Indexed as

AnimalsAntiprotozoal AgentsChagas DiseaseDNA, ProtozoanDrug Delivery SystemsGene Expression Regulation, EnzymologicGlycoproteinsModels, MolecularNeuraminidasePhylogenyProtein ConformationSelection, GeneticTriatomaTrypanosoma cruziAntiprotozoal AgentsDNA, ProtozoanGlycoproteinsNeuraminidasetrans-sialidaseChagas diseaseGenetic variationNatural selectionRational drug designTrans-sialidaseTriatoma dimidiataTriatoma nitidaTrypanosoma cruzi

Identifiers

PMID29684709
PMCPMC6196115
OpenAlexW2800087409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.